Smith & Nephew


A good finish to a progressive year

08/02/19 -"Smith & Nephew Q4/FY 2018 numbers were in line with estimates. Q4/FY 18 revenue was up by 3%/2% to $1,294m/$4,904m, driven by sports medicine joint repair, other surgical businesses and advanced ..."

Pages
55
Language
English
Published on
08/02/19
You may also be interested by these reports :
17/04/19
We have updated our forecasts following the FY 18 results. The solid top-line growth has continued to be boosted by the increase in contributions ...

16/04/19
On the back of both the strong operating performance and the accelerating external growth realised in 2018, the group has upgraded its 2019 guidance ...

09/04/19
The following chart shows how a lagging €42bn stock, EssilorLuxottica (Buy, France), can act as a brake to the otherwise brisk performance of a ...

02/04/19
Ups and downs After outgrowing the broader AV universe in the first two months of 2019, the MedTech sector continued to outperform the markets in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO